Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develo… Read more
Viridian Therapeutics Inc (VRDN) - Total Liabilities
Latest total liabilities as of December 2025: $177.25 Million USD
Based on the latest financial reports, Viridian Therapeutics Inc (VRDN) has total liabilities worth $177.25 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Viridian Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Viridian Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Viridian Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Viridian Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pennon Group Plc
PINK:PEGRF
|
USA | $6.02 Billion |
|
Eutelsat Group
LSE:ETL
|
UK | €4.34 Billion |
|
Western Union Co
NYSE:WU
|
USA | $6.86 Billion |
|
Hangzhou Great Star Industrial Co Ltd
SHE:002444
|
China | CN¥4.02 Billion |
|
Olympic Circuit Technology Co Ltd
SHG:603920
|
China | CN¥3.01 Billion |
|
First Hawaiian Inc
NASDAQ:FHB
|
USA | $21.19 Billion |
|
Hyosung Heavy Industries Corp
KO:298040
|
Korea | ₩4.62 Trillion |
|
Walsin Lihwa Corp
TW:1605
|
Taiwan | NT$121.80 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Viridian Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Viridian Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Viridian Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Viridian Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $177.25 Million | +150.48% |
| 2024-12-31 | $70.76 Million | +46.20% |
| 2023-12-31 | $48.40 Million | +20.92% |
| 2022-12-31 | $40.03 Million | +150.28% |
| 2021-12-31 | $15.99 Million | +42.57% |
| 2020-12-31 | $11.22 Million | -22.68% |
| 2019-12-31 | $14.51 Million | -1.99% |
| 2018-12-31 | $14.80 Million | +5.96% |
| 2017-12-31 | $13.97 Million | +204.71% |
| 2016-12-31 | $4.58 Million | +83.99% |
| 2015-12-31 | $2.49 Million | +18.78% |
| 2014-12-31 | $2.10 Million | +27.45% |
| 2013-12-31 | $1.65 Million | -93.20% |
| 2012-12-31 | $24.22 Million | -- |